Skip to main content
See every side of every news story
Published • loading... • Updated

Hyundai Bio Receives Approval for Additional Administration of ‘Penitrium’ to Patients Who Completed Phase 1 Prostate Cancer Clinical Trials

Summary by 조선일보
Hyundai Bio announced on the 17th that the Ministry of Food and Drug Safety has approved the use of the novel anticancer drug candidate ‘Penitrium (CP-PCA07)’ for the first patient participating in the Phase 1 clinical trial for prostate cancer, allowing the drug to continue to be administered even after the trial has concluded. The Phase 1 trial, currently underway at Seoul National University Hospital, involves a patient with metastatic castra…

4 Articles

Lean Right

Hyundai Bio announced on the 17th that the Ministry of Food and Drug Safety has approved the use of the novel anticancer drug candidate ‘Penitrium (CP-PCA07)’ for the first patient participating in the Phase 1 clinical trial for prostate cancer, allowing the drug to continue to be administered even after the trial has concluded. The Phase 1 trial, currently underway at Seoul National University Hospital, involves a patient with metastatic castra…

Left

On the 17th, Hyundai Bioscience (CEO Jin Geun-woo) announced that its novel anticancer drug candidate, ‘Penetrium (CP-PCA07)’, received approval from the Ministry of Food and Drug Safety on the 16th for use for individualized treatment. Regarding the first patient participating in the Phase 1 clinical trial for castration-resistant prostate cancer currently underway at Seoul National University Hospital

[Digital Daily, Reporter Wang Jinhwa] Hyundai Bioscience revealed the initial clinical observation results of 'Penitrium', a new drug candidate being developed for the purpose of overcoming resistance to anticancer drugs. The explanation is that prostate-specific antigen (PSA) levels decreased as a result of concomitant administration of phenytrium to prostate cancer patients who are resistant to existing anticancer drugs. Hyundai Bioscience ann…

Read Full Article

The logo of Hyundai Bioscience. [Photo courtesy of Hyundai Bioscience] South Korea’s Hyundai Bioscience announced on Nov. 19 that its experimental cancer drug Penetrium has shown promising results in an early-stage clinical trial involving patients with advanced prostate cancer who had developed resistance to conventional treatments. The Seoul-based biotechnology company noted that observations from an ongoing Phase 1 trial at Seoul National Uni…

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 50% of the sources lean Left, 50% of the sources lean Right
50% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

한겨레 broke the news on Tuesday, November 17, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal